KRAS G13D peptide, a 25-mer sequence, is derived from the KRAS activating oncogene mutation and serves as an immune potentiator. This peptide possesses immunogenic properties and can be utilized for the development of a KRAS vaccine.
U 92163 is synthetic peptidic transition state analog inhibitor that was used to determine the crystallographic structure of the protease from human immunodeficiency virus type 2.